Knowledge base · Peer-reviewed

ScaleWiki.

Peer-reviewed manuscripts on the G-Rex® platform — one citable page per paper, curated so you find the evidence that moves your cell & gene therapy program forward.

487Manuscripts indexed
14Cell types
Live indexContinuously updated

Showing 12 of 530 resources

Publications CAR T Cells G-Rex®24 Well Plate

Publication Date: May 22, 2025

Cell trajectory modulation: rapid microfluidic biophysical profiling of CAR T cell functional phenotypes

A label-free microfluidic assay, the cell trajectory modulation (CTM) assay, profiles CAR T cell size and deformability within 10 minutes from 20 μL of unprocessed culture sample. In anti-CD19 CAR T cells made from three healthy donors in either G-Rex® 24-well plates or the Breez microbioreactor, 21 of 88 CTM features differed significantly between platforms. Selected features correlated with flow cytometry phenotypes, including CD127+ cells, CD4:CD8 ratio and CAR expression, and with NALM6 specific lysis at a 1:5 effector-to-target ratio. A PCA-based biophysical index separated Breez (−0.083 ± 0.74) from G-Rex® (−1.90 ± 0.46) products on the final day of manufacture.

Download Now →

Author: Kerwin Kwek Zeming, Kai Yun Quek +11 more

Publications CAR T Cells

Publication Date: May 19, 2025

Optimized GMP-grade production of non-viral Sleeping Beauty-generated CARCIK cells for enhanced fitness and clinical scalability

Replacing T-flasks with G-Rex® bioreactors and delaying nucleofection to day 2 produced a simpler, feeder-free manufacturing process for Sleeping Beauty-engineered CARCIK-CD19 cells and a less differentiated product. Culture time fell from 21–28 days to 14–17 days. After transfer on day 7, cells stayed in the bioreactor for 10 days with IL-2 added every 3 days. Compared with flask-grown cells, G-Rex® cells were enriched in central memory, showed higher basal respiration and lower glycolysis scores. In Daudi lymphoma-bearing NSG mice, 10 × 10^6 G-Rex®-expanded CAR+ CIK cells controlled tumor growth, whereas 5 × 10^6 was insufficient. Seven GMP batches were produced at two cell factories; a…

Download Now →

Author: Ilaria Pisani, Giusi Melita +31 more

Publications CAR T Cells, NK Cells G-Rex®24 Well Plate

Publication Date: May 16, 2025

Engineering tripartite gene editing machinery for highly efficient non-viral targeted genome integration

Fusing Cas9 to short single-stranded DNA binding motifs lets the nuclease tether circular single-stranded DNA donors, which raises non-viral knock-in efficiency across cell types. A 20-amino-acid RecA-derived motif (FECO) performed like full-length RecA, giving about 1.6-fold more GFP knock-in than unfused Cas9 at RAB11A in K562 cells, and the gain required a single-stranded donor. With mRNA editors, 2 kb knock-in rose from 30.10% to as high as 48.5%, and an 8 kb payload from about 3% to about 5%. In primary human T cells, a roughly 3 kb CD19-CD22 dual CAR cassette was integrated at TRAC in 30.2% to 33.4% of cells versus 5% to 14.1% with unfused Cas9, and these CAR-T cells killed NALM6 le…

Download Now →

Author: Hangu Nam, Keqiang Xie +8 more

Publications T-Cells

Publication Date: May 14, 2025

A Novel B7-H4xCD3 Bispecific T Cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune-Checkpoint Therapies

PF-07260437, a bispecific antibody that binds B7-H4 on tumor cells and CD3 on T cells, redirected human T cells to kill breast cancer cells of all three major molecular subtypes and caused durable tumor regressions in mice. B7-H4 was detected in 95% of 61 primary breast cancer specimens, and cell lines with higher B7-H4 density showed lower EC50 values (R² = 0.8045). In T-47D xenografts given expanded human T cells, 0.5 mg/kg cleared tumors in 10 of 10 mice with no regrowth at 35 days. In an immunocompetent mouse model expressing human CD3e, a single dose gave 72% tumor growth inhibition, rising to 106% with anti-PD-1. CD8-PET imaging tracked dose-dependent CD8 T cell infiltration, and cy…

Download Now →

Author: Keith Abayasiriwardana, Lei Wu +35 more

Publications CAR T Cells

Publication Date: May 13, 2025

An Analysis of Monitoring Solutions for CAR T Cell Production

Most monitoring of CAR T cell manufacturing still depends on off-line or at-line measurements, which are a bottleneck for digital, real-time process control. This literature review of the production steps (selection, activation, gene transfer, expansion and formulation) catalogued 47 measurement methods and sorted them as off-line, at-line, on-line or in-line, together with their data formats and real-time capability. Key parameters were assigned to each step, split into core and research metrics. Cell count and viability can currently be measured only off-line. Optical biosensors and soft sensors, particularly hybrid models, are presented as promising routes toward continuous monitoring,…

Download Now →

Author: Arber Shoshi, Yuchen Xia +9 more

Publications T-Cells, TCR T Cells G-Rex®100M-CS, G-Rex®24 Well Plate, G-Rex®500M-CS, G-Rex®6 Well Plate

Publication Date: May 12, 2025

Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discovery

A single ex vivo process applied to peripheral blood from 20 healthy donors primed and expanded CD8+ T cells against 46 of the 47 KRAS G12D and G12V neoantigens evaluated. Replacing restimulation with a day-14 enrichment for activation markers raised the antigen-specific fraction 6- to 52-fold, and seeding at 3-6 million cells/cm2 in G-Rex® vessels with day-5 IL-2 plus a CD3/CD28 agonist at the start of expansion raised the median number of mKRAS-specific CD8+ T cells 14-fold, with nine of 10 runs reaching 50 million. G12V responses exceeded G12D (median 20.8% versus 2.2%). The product slowed tumor growth in mice, and among 154 cloned TCRs several showed avidity and cytotoxicity comparabl…

Download Now →

Author: Brandon P. Conn, Jared L. Dietze +8 more

Publications T-Cells G-Rex®50M, G-Rex®6M Well Plate

Publication Date: May 1, 2025

Scalable Manufacturing of T Cells Using cGMP-Compliant Ancillary Reagents

STEMCELL Technologies' cGMP-compliant ImmunoCult activator and ImmunoCult-XF medium supported robust expansion of human T cells in three closed, scalable bioreactor platforms. In G-Rex® 6M well plates, cells seeded at 1–2 × 10^6 cells/cm² and expanded for 10 days reached about 4 × 10^7 T cells/cm² with the lower activator dose, the device's maximum capacity, and central memory cells exceeded 1 × 10^7 cells/cm². In G-Rex® 50M, 7-day cultures yielded more than 1 × 10^9 cells per device. Xuri W25 cultures reached 503 ± 51-fold expansion and PBS-MINI MagDrive cultures 614 ± 108-fold expansion by day 10. Cells from G-Rex® 6M plates showed robust cytotoxicity against NALM-6 cells, and Xuri-expa…

Download Now →

Author: Nooshin Tabatabaei-Zavareh, Jessie Yu +6 more

Publications CAR T Cells G-Rex®6M Well Plate

Publication Date: May 1, 2025

High-dimensional temporal mapping of CAR T cells reveals phenotypic and functional remodeling during manufacturing

Harvest timing determined which cell states anti-CD19 CAR T cell products contained: day-5 products were dominated by proliferative, metabolically active CD4+ Th1 cells, whereas day-10 products shifted toward terminally differentiated CD8+ Tc1 cells and NK-like T cells. Lentivirally transduced products from six healthy donors were profiled at days 0, 5 and 10 with a 36-marker spectral flow cytometry panel. Stem cell memory cells reached 25.0% of CAR+ cells at day 5 and 11.5% at day 10, while terminal effectors expanded from 36.3% to 61.5%. CAR+ and CAR− cells followed similar trajectories, suggesting expansion conditions may shape product identity more than gene transfer. Day-5 and day-10…

Download Now →

Author: Amaia Cadinanos-Garai, Christian L. Flugel +4 more

Publications CD34 Cells G-Rex®24 Well Plate, G-Rex®6 Well Plate

Publication Date: April 22, 2025

Donor insertion into CX3CR1 allows epigenetic modulation of a constitutive promoter on hematopoietic stem cells and its activation upon myeloid differentiation

Inserting a constitutive SFFV-eGFP cassette into intron 1 of CX3CR1 in human cord blood HSPCs, a strategy called KI-Ep, gave low expression in primitive cells and strong expression after myeloid differentiation. Editing used Cas9 RNP electroporation with an AAV6 donor carrying 300 nt homology arms; CAST-Seq found no off-target translocations. In culture, eGFP+ cells were 1.4–3.8-fold more frequent in the most differentiated CD34− subsets than in CD34+ primitive subsets, whereas lentiviral controls expressed at similar levels in all subsets. In NSG mice at 21 weeks, myeloid CD11b+ cells showed about 5-fold more eGFP+ cells and over 20-fold higher eGFP intensity than long-term HSPCs. ChIP-q…

Download Now →

Author: Iris Ramos-Hernández, Carla Fuster-García +9 more

Publications CAR T Cells G-Rex®24 Well Plate

Publication Date: April 20, 2025

MARC, a novel modular chimeric antigen receptor, improves T cell- based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence

A modular chimeric antigen receptor called MARC, built on the assembly principles of native activating immune receptors, removes tonic signaling and improves T cell persistence compared with a conventional CD28-CD3ζ CAR. Charge-shifted transmembrane registries drove selective assembly of receptor and signaling modules, and a CD3ζ signaling module increased ITAMs from 2 to 6. In primary T cells, MARC-T cells expressed roughly four times fewer surface receptors yet showed similar functional avidity, killed low-density targets better and formed stable synapses. In NSG mice with NALM6 leukemia, nearly twice as many MARC-T cells as CAR-T cells were recovered from spleens, with lower PD1 and LA…

Download Now →

Author: Margaux Tual, Angélique Bellemare-Pelletier +9 more

Publications γδ T

Publication Date: April 16, 2025

Dual modulation of cytotoxic and checkpoint receptors tunes the efficacy of adoptive Delta One T cell therapy against colorectal cancer

Delta One T (DOT) cells, a Vδ1+ γδ T cell product, killed colorectal cancer cell lines, patient tumor specimens and patient-derived organoids in vitro and slowed tumor growth in an orthotopic mouse model. Inside tumors, however, the infused cells lost NKG2D and DNAM1 and showed reduced degranulation, granzyme B, perforin, TNF and IFNγ, while upregulating TIGIT and PD1. The same imbalance appeared in Vδ1+ tumor-infiltrating lymphocytes from patients. Giving butyrate raised NKG2D ligands on tumor cells and improved killing, and combined anti-PD1 (nivolumab) plus anti-TIGIT (vibostolimab) gave the strongest tumor control in mice, whereas single blockade had minor effects. NKG2D knockout impa…

Download Now →

Author: Rafael Blanco-Domínguez, Leandro Barros +11 more

Publications VST Cells

Publication Date: April 9, 2025

Donor Variability and PD-1 Expression Limit BK Polyomavirus-specific T-cell Function and Therapy

Expanding BK polyomavirus-specific T cells in G-Rex® vessels gave higher cell counts than conventional plate culture, but responses varied between donors and PD-1 expression rose, which may limit adoptive therapy. PBMCs from healthy BKPyV-seropositive donors were stimulated with overlapping peptide pools and expanded with IL-2 and IL-7. The difference in cell count was most significant on day 10 (P = 0.001), and CD4 T cells outnumbered CD8 T cells by more than 3:1. Expanded cells produced IFN-γ and TNF-α, degranulated, and killed peptide-pulsed autologous blasts and BKPyV-infected kidney tubular cells, with survival of infected cells reduced by about 35%. Pembrolizumab lowered PD-1 and en…

Download Now →

Author: Maud Wilhelm, Amandeep Kaur +3 more